当前位置:首页 - 行情中心 - 尔康制药(300267) - 财务分析 - 现金流量表

尔康制药

(300267)

  

流通市值:33.71亿  总市值:48.88亿
流通股本:14.22亿   总股本:20.63亿

现金流量表

报告期2024-09-302024-06-302024-03-312023-12-31
公司类型通用通用通用通用
一、经营活动产生的现金流量:
销售商品、提供劳务收到的现金854,076,763.42610,232,751.6262,689,455.211,774,936,384.53
收到的税费返还23,609,449.5723,609,449.571,930,905.4414,051,379.74
收到其他与经营活动有关的现金74,404,389.543,678,610.4431,635,311.06413,835,090.33
经营活动现金流入的平衡项目0000
经营活动现金流入小计952,090,602.49677,520,811.61296,255,671.712,202,822,854.6
购买商品、接受劳务支付的现金438,224,548.78333,835,584.44190,264,929.161,240,754,296.04
支付给职工以及为职工支付的现金126,148,792.3687,822,436.3349,816,248.67166,589,414.18
支付的各项税费50,339,085.7537,723,283.7-3,852,410.0972,057,340.02
支付其他与经营活动有关的现金261,563,935.3890,510,530.4949,327,683.15575,001,067.22
经营活动现金流出的平衡项目0000
经营活动现金流出小计876,276,362.27549,891,834.96285,556,450.892,054,402,117.46
经营活动产生的现金流量净额平衡项目0000
经营活动产生的现金流量净额75,814,240.22127,628,976.6510,699,220.82148,420,737.14
二、投资活动产生的现金流量:
收回投资收到的现金210,434,000150,434,000100,434,000833,348,000
取得投资收益收到的现金1,899,061.741,506,828.86654,708.3312,807,900.26
处置固定资产、无形资产和其他长期资产收回的现金净额181,300150,000150,00020,113,086.5
收到的其他与投资活动有关的现金705,000---
投资活动现金流入的平衡项目0000
投资活动现金流入小计213,219,361.74152,090,828.86101,238,708.33866,268,986.76
购建固定资产、无形资产和其他长期资产支付的现金164,305,107.0199,226,607.3851,671,254.89238,187,429.42
投资支付的现金310,202,000250,202,000250,202,000733,000,000
投资活动现金流出的平衡项目0000
投资活动现金流出小计474,507,107.01349,428,607.38301,873,254.89971,187,429.42
投资活动产生的现金流量净额平衡项目0000
投资活动产生的现金流量净额-261,287,745.27-197,337,778.52-200,634,546.56-104,918,442.66
三、筹资活动产生的现金流量:
取得借款收到的现金307,700,000257,700,000157,700,000341,000,000
收到其他与筹资活动有关的现金200,000,000200,000,000150,144,027.78146,589,229.31
筹资活动现金流入平衡项目0000
筹资活动现金流入小计507,700,000457,700,000307,844,027.78487,589,229.31
偿还债务支付的现金259,000,000259,000,000149,000,000380,133,502.64
分配股利、利润或偿付利息支付的现金7,323,231.556,190,098.213,345,437.170,097,190.11
支付其他与筹资活动有关的现金103,203,261.3951,155,188.77611,731.39203,364,626.22
筹资活动现金流出平衡项目0000
筹资活动现金流出小计369,526,492.94316,345,286.98152,957,168.49653,595,318.97
筹资活动产生的现金流量净额平衡项目0000
筹资活动产生的现金流量净额138,173,507.06141,354,713.02154,886,859.29-166,006,089.66
四、汇率变动对现金及现金等价物的影响-9,550,453.85-7,918,486.54-5,846,037.81201,122.18
现金及现金等价物净增加额平衡项目0000
五、现金及现金等价物净增加额-56,850,451.8463,727,424.61-40,894,504.26-122,302,673
加:期初现金及现金等价物余额510,637,726.36510,637,726.36510,637,726.36632,940,399.36
期末现金及现金等价物余额平衡项目0000
期末现金及现金等价物余额453,787,274.52574,365,150.97469,743,222.1510,637,726.36
补充资料:
净利润-6,338,336.65--221,853,783.74
资产减值准备--3,073,048.43-122,652,855.09
固定资产和投资性房地产折旧-80,900,181.99-174,068,938.64
其中:固定资产折旧、油气资产折耗、生产性生物资产折旧-80,900,181.99-174,068,938.64
无形资产摊销-11,422,647.55-25,205,581.69
长期待摊费用摊销-1,710,105.76-7,810,657.19
处置固定资产、无形资产和其他长期资产的损失----8,803,061.2
固定资产报废损失---4,973,747.79
公允价值变动损失--419,800-14,536,527.53
财务费用-14,239,514.26-3,580,249.45
投资损失--935,164.92--5,463,278.42
递延所得税-775,613.68-9,569,457.92
其中:递延所得税资产减少-407,401.16-16,779,064.16
递延所得税负债增加-368,212.52--7,209,606.24
存货的减少-754,521.76-46,968,832.38
经营性应收项目的减少-17,200,704.16--19,957,401.09
经营性应付项目的增加--22,991,779.09-8,583,577.22
其他-19,414,261.63--18,468,981.11
现金的期末余额-574,365,150.97-510,637,726.36
减:现金的期初余额-510,637,726.36-632,940,399.36
公告日期2024-10-252024-08-292024-04-272024-04-25
审计意见(境内)标准无保留意见
TOP↑